145 related articles for article (PubMed ID: 31184233)
1. Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.
Xu D; Claudiani S; Naresh K; Mucklow S; Neelakantan P; Yebra E; Apperley JF; Khorashad J; Milojkovic D
Leuk Lymphoma; 2019 Dec; 60(12):3090-3091. PubMed ID: 31184233
[No Abstract] [Full Text] [Related]
2. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.
Pullarkat ST; Vardiman JW; Slovak ML; Rao DS; Rao NP; Bedell V; Said JW
Leuk Res; 2008 Nov; 32(11):1770-5. PubMed ID: 18417213
[TBL] [Abstract][Full Text] [Related]
3. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.
Xue M; Wang Q; Huo L; Wen L; Yang X; Wu Q; Pan J; Cen J; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2019 Dec; 60(12):3051-3057. PubMed ID: 31258010
[TBL] [Abstract][Full Text] [Related]
5. Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
Moschovi M; Adamaki M; Athanasiadou A; Divane A; Karytianou A; Tourkantoni N
Leuk Lymphoma; 2015; 56(8):2460-2. PubMed ID: 25641431
[No Abstract] [Full Text] [Related]
6. A rare BCR-ABL1 transcript in chronic myeloid leukemia: Case report and literature review.
Zhao ZY; Tang N; Lin LE
Leuk Res; 2023 Oct; 133():107369. PubMed ID: 37660636
[TBL] [Abstract][Full Text] [Related]
7. Aleukemic Extramedullary Blast Crisis as an Initial Presentation of Chronic Myeloid Leukemia with E1A3 BCR-ABL1 Fusion Transcript.
Miyashita N; Onozawa M; Suto K; Fujisawa S; Okazaki N; Hidaka D; Ohigashi H; Yasumoto A; Sugita J; Hashimoto D; Matsuno Y; Teshima T
Intern Med; 2022 Apr; 61(7):1049-1054. PubMed ID: 34511573
[TBL] [Abstract][Full Text] [Related]
8. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
9. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
[No Abstract] [Full Text] [Related]
10. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
[TBL] [Abstract][Full Text] [Related]
11. Emergence of secondary fusions in chronic myeloid leukemia as a driver of tyrosine kinase inhibitor resistance and blast crisis transformation.
Boucher L; Rozalska L; Sorel N; Olivier G; Hernanz MPG; Cayssials E; Raimbault A; Chomel JC
Leuk Res; 2024 Feb; 137():107439. PubMed ID: 38281466
[No Abstract] [Full Text] [Related]
12. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shah NP; Bhatia R; Altman JK; Amaya M; Begna KH; Berman E; Chan O; Clements J; Collins RH; Curtin PT; DeAngelo DJ; Drazer M; Maness L; Metheny L; Mohan S; Moore JO; Oehler V; Pratz K; Pusic I; Rose MG; Shomali W; Smith BD; Styler M; Talpaz M; Tanaka TN; Tantravahi S; Thompson J; Tsai S; Vaughn J; Welborn J; Yang DT; Sundar H; Gregory K
J Natl Compr Canc Netw; 2024 Feb; 22(1):43-69. PubMed ID: 38394770
[TBL] [Abstract][Full Text] [Related]
13. Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Buxhofer-Ausch V; Hinterberger-Fischer M; Hinterberger W
Eur J Haematol; 2006 May; 76(5):447-8. PubMed ID: 16494624
[No Abstract] [Full Text] [Related]
14. BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis.
Kidoguchi K; Kojima K; Yokoo M; Kimura S
Ann Hematol; 2019 Oct; 98(10):2461-2462. PubMed ID: 31399807
[No Abstract] [Full Text] [Related]
15. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
Togitani K; Asagiri T; Kamioka M; Kojima K
Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3
Massimino M; Stella S; TirrĂ² E; Consoli ML; Pennisi MS; Puma A; Vitale SR; Romano C; Zammit V; Stagno F; DI Raimondo F; Manzella L
Anticancer Res; 2019 Jul; 39(7):3949-3954. PubMed ID: 31262926
[TBL] [Abstract][Full Text] [Related]
17. Cadherin-13 in primary and blast crisis chronic myeloid leukaemia: declining expression and negative correlation with the BCR/ABL fusion gene.
Mu HJ; Xie R; Shen YF; Jiang YQ; Zeng YJ
Br J Biomed Sci; 2009; 66(1):20-4. PubMed ID: 19348122
[TBL] [Abstract][Full Text] [Related]
18. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
[TBL] [Abstract][Full Text] [Related]
19. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Lindner I; Kharfan-Dabaja MA; Ayala E; Kolonias D; Carlson LM; Beazer-Barclay Y; Scherf U; Hnatyszyn JH; Lee KP
J Immunol; 2003 Aug; 171(4):1780-91. PubMed ID: 12902478
[TBL] [Abstract][Full Text] [Related]
20. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
[No Abstract] [Full Text] [Related]
[Next] [New Search]